Table 4.
Comparison of AUC-CSHtotal and AUC-CSH40% between different subgroups
| Variable | AUC-CSH40% | P | AUC-CSHtotal | P | |
|---|---|---|---|---|---|
| COG | 0.965 | 0.018* | |||
| Low and medium risk | 0.560±0.060 | 0.506±0.108 | |||
| High risk | 0.561±0.039 | 0.431±0.079 | |||
| BMI | |||||
| No | 0.563±0.070 | 0.914 | 0.516±0.113 | 0.030* | |
| Yes | 0.560±0.038 | 0.441±0.007 | |||
| MYCN | |||||
| Normal | 0.560±0.054 | 0.947 | 0.465±0.113 | 0.861 | |
| Acquired and amplify | 0.561±0.039 | 0.459±0.077 | |||
| EFS | |||||
| Without event | 0.581±0.049 | 0.009* | 0.515±0.101 | <0.001* | |
| With event | 0.541±0.039 | 0.410±0.062 | |||
COG Children's Oncology Group, BMI bone morrow involvement, MYCN myelocytomatosis viral oncogene neuroblastoma derived homolog, EFS event-free survival, AUC-CSH areas under the curve of cumulative SUV-volume histogram, *P < 0.05